MedWatch

Analyst deems Novo Nordisk once-weekly insulin has blockbuster potential

Even so, the analyst from Danish bank Sydbank doesn’t think insulin icodec will reach the same level as the pharmaceutical giant’s popular GLP-1 drugs.

Photo: Niels Hougaard/ERH

Novo Nordisk’s experimental new type 2 diabetes insulin icodec has the potential to reach blockbuster heights, which is achieved once a drug generates more than USD 1bn within a financial year, assesses Søren Løntoft Hansen, senior equity analyst at Danish bank Sydbank.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs